GLUCOSE 20 % Israël - Engels - Ministry of Health

glucose 20 %

lapidot medical import and marketing ltd - glucose as monohydrate - solution for infusion - glucose as monohydrate 20 % - glucose - glucose - high caloric carbohydrate infusion hypoglycaemia.

OCSAAR PLUS Israël - Engels - Ministry of Health

ocsaar plus

organon pharma israel ltd., israel - hydrochlorothiazide; losartan potassium - tablets - losartan potassium 50 mg; hydrochlorothiazide 12.50 mg - losartan and diuretics - losartan and diuretics - ocsaar plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hyperfension adn left ventricular hypertrophy.

CO-DIOVAN 8012.5 MG FILM COATED TABLETS Israël - Engels - Ministry of Health

co-diovan 8012.5 mg film coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

CO-DIOVAN 16012.5 MG FILM-COATED TABLETS Israël - Engels - Ministry of Health

co-diovan 16012.5 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

CO-DIOVAN 16025 MG FILM-COATED TABLETS Israël - Engels - Ministry of Health

co-diovan 16025 mg film-coated tablets

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

GIROFLOX Israël - Engels - Ministry of Health

giroflox

bioavenir ltd, israel - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg / 100 ml - ciprofloxacin - ciprofloxacin - * adults :broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens.* children and adolescents:• broncho-pulmonary infections in cystic fibrosis caused by pseudomonas aeruginosa• complicated urinary tract infections and pyelonephritis• inhalation anthrax (post-exposure prophylaxis and curative treatment)ciprofloxacin may also be used to treat severe infections in children and adolescents when there is no otheralternative .treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents

OXALIPLATIN MEDAC 50 MG Israël - Engels - Ministry of Health

oxaliplatin medac 50 mg

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 50 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

OXALIPLATIN MEDAC 100 MG Israël - Engels - Ministry of Health

oxaliplatin medac 100 mg

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 100 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

OXALIPLATIN MEDAC 150 MG Israël - Engels - Ministry of Health

oxaliplatin medac 150 mg

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

MABTHERA 10 MGML I.V Israël - Engels - Ministry of Health

mabthera 10 mgml i.v

roche pharmaceuticals (israel) ltd - rituximab - concentrate for solution for infusion - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plus chemotherapy.* rheumatoid arthritismabthera is indicated, in combination with methotrexate, to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to one or more tnf antagonist therapies.* granulomatosis with polyangiitis and microscopic polyangiitismabthera, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (gpa) (wegener’s granulomatosis (wg) and microscopic polyangiitis (mpa). *pemphigus vulgarismabthera is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (pv).